Year All2024202320222021 January 5, 2024 ArriVent Appoints Winston Kung as Chief Financial Officer and Treasurer October 30, 2023 ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations September 20, 2023 ArriVent Appoints Chris Nolet to its Board of Directors September 10, 2023 Furmonertinib Shows Encouraging Efficacy in EGFR Exon20Ins Mut+ NSCLC September 10, 2023 Allist and Arrivent Announce interim Results from Ongoing Phase 1b Trial with Furmonertinib at the 2023 World Conference on Lung Cancer July 13, 2023 InnoCare and ArriVent Announce Clinical Development Collaboration March 27, 2023 ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing July 5, 2022 ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations February 15, 2022 ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors December 31, 2021 Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform
October 30, 2023 ArriVent Receives FDA Breakthrough Therapy Designation for Furmonertinib for First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
September 10, 2023 Allist and Arrivent Announce interim Results from Ongoing Phase 1b Trial with Furmonertinib at the 2023 World Conference on Lung Cancer
July 5, 2022 ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations
December 31, 2021 Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform
